---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-089737"
form_type: "8-K"
ticker: "CGTX"
cik: "0001455365"
company_name: "COGNITION THERAPEUTICS INC"
filed_at: "2025-09-15T23:59:59+00:00"
generated_at: "2026-05-17T06:36:59.283517+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# Cognition Therapeutics' investor deck highlights Zervimesine Phase 3 progress

## Summary
- Presentation focuses on Zervimesine, a once-daily oral therapeutic for neurodegenerative diseases.
- Zervimesine is described as advancing toward Phase 3, but no specific trial dates or results disclosed.
- No financial results, guidance, or material operational updates included in the filing.

## SEC filing metadata
- accession: 0001104659-25-089737
- form_type: 8-K
- ticker: CGTX
- cik: 0001455365
- company_name: COGNITION THERAPEUTICS INC
- filed_at: 2025-09-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1455365/000110465925089737/0001104659-25-089737-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1455365/000110465925089737/tm2525997d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-089737
- JSON: https://secwatch.observer/filing/0001104659-25-089737.json
- Plain text: https://secwatch.observer/filing/0001104659-25-089737.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.